Northwestern Medicine scientists have described a method of reconstructing the three-dimensional structure of chromosomes in cancer cells and matching those chromosomes with counterpart oncogenes.
For the first time, scientists have examined how the three-dimensional structure of chromatin can play a part in the development of bladder cancer and pediatric brain tumors, according to a pair of Northwestern Medicine studies.
Using small molecular inhibitors to block the BAP1 complex may be a promising targeted therapy approach for leukemia, according to a Northwestern Medicine study published in Nature Cancer.
Two Northwestern Medicine studies are improving the understanding of epigenetic mechanisms in cancer development and progression, and identifying novel cancer driver genes that may help identify patients who will benefit from immunotherapy.
A team of Northwestern Medicine investigators led by Rina Fox, PhD, MPH, received a Cancer and Aging Translational Bridge Award to investigate circadian disruption in lymphoma.
An FDA-approved monoclonal antibody drug used to treat advanced bladder cancer demonstrated poor efficacy in a recent clinical trial.
Boosting mitochondrial function in a subpopulation of T cells could make cancer immunotherapy more effective, according to a recent study.
Northwestern Medicine scientists have discovered a mechanism that makes a prostate cancer-causing protein called FOXA1 more resilient, according to a recent study.
Northwestern Medicine investigators have discovered how a particular type of immune cell exerts a dual function in cancer cells that is contingent on tumor grade.
Inhibiting production of a key material produced by the mTOR pathway could slow tumor growth, according to a recent Northwestern Medicine study.